US-based biopharmaceutical company Second Genome raised $42.6m yesterday in a series B round co-led by pharmaceutical firms Pfizer and Roche, which invested through their respective Pfizer Venture Investments and Roche Venture Fund units.

Medical research organisation Mayo Clinic also took part in the round, as did Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group and angel investor Matthew Winkler.

Founded in 2009, Second Genome is developing drugs for a range of inflammatory bowel…